Rob Hunter PhD
Rob Hunter, PhD in Veterinary Pharmacology, has twenty-five years of veterinary and human drug development experience with NASA, Pfizer (Animal Health), Elanco, Parnell, and Provetica. Dr. Hunter has contributed to the US and/or global approvals of Revolution®, Dectomax®, Aviax®, Doxidyl™, A180®, tylosin, Micotil®, Ovugel®, Kexxtone®, ractopamine, Experior, Posilac®, and Pulmotil® with others in development or under regulatory review. He is an internationally recognized subject matter expert on pharmacokinetics, antimicrobial PK/PD, interspecies allometry, drug metabolism, BE, and tissue residues/human food safety (CVM/FDA GFI #3) along with corresponding bioanalytical support.
Dr. Hunter has served on and chaired several Animal Health Institute committees and represented the U.S. veterinary pharmaceutical industry on the VICH BE expert committee. He has also represented various companies at CVM/FDA, EMA/CVMP, APVMA, VDD (Canada), NVQRS/QIA (South Korea), Thailand FDA, NVAL (Japan), Ministry of Agriculture (Vietnam), and IVDC (China) meetings regarding specific products, issues, and/or policies.
Dr. Hunter is currently an adjunct professor at the University of Kansas and an instructor at Kansas State University as well as the current President of the American Academy of Veterinary Pharmacology and Therapeutics. He also serves as a member of the Editorial Boards for the Journal of Veterinary Pharmacology & Therapeutics, Journal of Zoo & Wildlife Medicine, Research in Zoology, American Journal of Bioavailability & Bioequivalence, and the Journal of Primates.
Dr. Hunter completed his PhD in Veterinary Pharmacology at Louisiana State University and his MS in Veterinary Physiology at Texas A&M University.